<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H361A99753CBB487D93EF640CE02E46F3" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>119 HR 5467 IH: Patient Access to Autoimmune Treatments Act</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2025-09-18</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">119th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 5467</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20250918">September 18, 2025</action-date><action-desc><sponsor name-id="J000310">Ms. Johnson of Texas</sponsor> (for herself and <cosponsor name-id="K000403">Mr. Kennedy of Utah</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name>, and in addition to the Committee on <committee-name committee-id="HWM00">Ways and Means</committee-name>, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned</action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend title XVIII of the Social Security Act to require coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D.</official-title></form><legis-body id="H414AAC00FD714E0C8E12CCF5E91D30D8" style="OLC"> 
<section id="H7784F779286144F79213AC9AC65BFEFA" section-type="section-one"><enum>1.</enum><header>Short title</header>
 <text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Patient Access to Autoimmune Treatments Act</short-title></quote> or the <quote><short-title>PAAT Act</short-title></quote>.</text></section> 
<section id="H66F31B5F246A471D8411C243F92B3ED0"><enum>2.</enum><header>Requiring coverage of drugs for autoimmune diseases and certain blood disorders under Medicare part D</header><text display-inline="no-display-inline">Section 1860D–4 of the Social Security Act (<external-xref legal-doc="usc" parsable-cite="usc/42/1395w-104">42 U.S.C. 1395w–104</external-xref>) is amended—</text> <paragraph id="H14811D72E0CE45EF9D780D6C01E58F23"><enum>(1)</enum><text>in subsection (b)(3), by adding at the end the following new subparagraph:</text> 
<quoted-block style="OLC" id="HDBCB27A23B9A4FE6B6E7AF911CE1A5F8" display-inline="no-display-inline"> 
<subparagraph id="H0425020DEE334CE3A48CDC5047776B2B"><enum>(J)</enum><header>Required inclusion of certain drugs for autoimmune diseases and blood disorders</header> 
<clause id="H7499C8BED59944A8A948F8C365CAC324"><enum>(i)</enum><header>In general</header><text display-inline="yes-display-inline">For 2027 and each subsequent year, a PDP sponsor offering a prescription drug plan shall include each covered part D drug that is an autoimmune or blood disorder drug described in <internal-xref idref="HE63EB5A7D49E401D98F8407DDD5DA353" legis-path="(I)(ii)">clause (ii)</internal-xref>.</text></clause> <clause id="HE63EB5A7D49E401D98F8407DDD5DA353"><enum>(ii)</enum><header>Autoimmune or blood disorder drug</header><text>For purposes of <internal-xref idref="H7499C8BED59944A8A948F8C365CAC324" legis-path="(I)(i)">clause (i)</internal-xref>, a drug described in this clause is a covered part D drug indicated and prescribed for the treatment of an autoimmune disease, hemophilia, or Von Willebrand disease.</text> </clause></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph> 
<paragraph id="H7A1EBC2D21D14573A7E9819844D4E7C2"><enum>(2)</enum><text>in subsection (c)—</text> <subparagraph id="HAB06767E5D1A4351BF2ED7AB2D6633F4"><enum>(A)</enum><text display-inline="yes-display-inline">by redesignating paragraph (6), as added by section 50354 of division E of the Bipartisan Budget Act of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/123">Public Law 115–123</external-xref>), as paragraph (7); and</text></subparagraph> 
<subparagraph id="H81EAA921DBA14574BE7443C31EA0E117"><enum>(B)</enum><text>by adding at the end the following new paragraph:</text> <quoted-block style="OLC" id="HB54EC5E01CE241A6B5DCFBD9FDF43679" display-inline="no-display-inline"> <paragraph id="H98EB53B6673E4C0EBB26325A2455D2DF"><enum>(8)</enum><header>Prohibition on use of prior authorization for certain autoimmune or blood disorder drugs</header><text>For plan years beginning on or after January 1, 2027, a PDP sponsor offering a prescription drug plan (and an MA organization offering an MA–PD plan) may not require, with respect to an individual enrolled under such plan, that prior authorization for an autoimmune or blood disorder drug (as described in subsection (b)(3)(J)(ii)) be obtained more than once during any 12-month period unless such drug is—</text> 
<subparagraph id="H690B4AAD49BF44EAB8D727AD700840E1" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">typically used for a period of 12 months or less;</text></subparagraph> <subparagraph id="H357481BC490143219B037FD67C316E17" commented="no"><enum>(B)</enum><text>an opioid, a benzodiazepine, a barbiturate, or carisoprodol; or</text> </subparagraph> 
<subparagraph id="H253765AD77F84DC8AB32707AF91AB05C" commented="no"><enum>(C)</enum><text display-inline="yes-display-inline">a drug with respect to which a risk evaluation and mitigation strategy is required under Section 505–1 of the Federal Food, Drug, and Cosmetic Act.</text> </subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subparagraph></paragraph> </section> </legis-body></bill>

